Table 3.

Summary of calcimimetic study characteristics and VC outcome

Author and Year	Type of Study	Study Duration (months)	Participant	Intervention (Participants at Baseline)	Comparator (Participants at Baseline)	VC as Primary or Secondary End Point	VC Imaging	VC Site	VC Outcome
Tsurata 200851a	Non-RCT	7–13	HD, SHPT	Cinacalcet, n=8	Control condition undefined, n=60	Primary	CT	Coronary artery	Less progression with cinacalcet
Raggi 201152 (ADVANCE)	RCT	12	HD, SHPT	Cinacalcet + low-dose vitamin D, n=180	Flexible doses of vitamin D, n=180	Primary: % change in Agatston CAC score, secondary: % & absolute change for other sites	CT	Coronary arteries, thoracic aorta, aortic valve, mitral valve	Less progression at aortic valve with cinacalcet. Primary outcome no significant difference
Nakayama 201453	Non-RCT	36	HD, SHPT	Cinacalcet, n=23	No control group	Primary	CT	Abdominal aorta	Less progression with cinacalcet
Cruzado 201654	RCT	12	Kidney transplant recipients	Cinacalcet, n=15	Subtotal parathyroidectomy, n=15	Secondary	CT	Thoracic/abdominal aorta; iliac arteries	No significant VC attenuation at all sites
Susantitaphong 201955	Non-RCT	8.3 (36 weeks)	HD, SHPT	Phase 2: 12 weeks of cinacalcet, n=45	Phase 2: no control group	Secondary	X-ray lateral	Not reported	Less progression with cinacalcet
Eddington 202156	RCT	12	HD, SHPT	Cinacalcet, n=15	Standard treatment, n=21	Primary	CT	Coronary artery, abdominal aorta	No significant difference at both sites

^aTsurata 2008⁵¹ was included in the study participants median and range, but excluded from the study duration median and range calculations due to the duration provided being a range from 7 to 13.

HD, hemodialysis.